Idle thoughts of a 'well-calibrated' Bayesian in clinical drug development

Pharmaceutical Statistics

Volumn 15, Issue 2, 2016, Pages 96-108

  Grieve, Andrew P ^a  

^a ICON PLC   (United Kingdom)

Author keywords

Bayesian statistics; calibration; drug development; operating characteristics; planning; simulation

Indexed keywords

BAYES THEOREM; CALIBRATION; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG DOSE; HUMAN; MEDICAL RESEARCH; MONITORING; PRACTICE GUIDELINE; PROBABILITY; RANDOMIZATION; REVIEW; STANDARDIZATION; STATISTICAL ANALYSIS; STATISTICAL DISTRIBUTION; STATISTICAL MODEL; STUDY DESIGN; FOOD AND DRUG ADMINISTRATION; PROCEDURES; STANDARDS; STATISTICS AND NUMERICAL DATA; UNITED STATES;

BAYES THEOREM; CALIBRATION; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; MODELS, STATISTICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84955493890     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1736     Document Type: Review

References (110)

1. Bayes T,. An essay towards solving a problem in the doctrine of chances. Philosophical Transactions of the Royal Society 1763; 53: 370-418.
2. Laplace PS,. Mémoire sur la probabilité des causes par les évenemens. Mémoires de mathématique et de physique presentés a l'Académie royale des sciences, par divers savans, & lûs dans ses assemblées 1774; 6: 621-656.
3. Helmert FR,. Über die Bestimmung des wahrscheinlichen Fehlers aus einer endlichen Anzahl wahrer Beobachtungsfehler. Zeitschrift für Mathematik und Physik 1875; 20: 300-3.
4. Helmert FR,. Über die Wahrscheinlichkeit der Potenzsummen der Beobachtungsfehler und uber einige damit in Zusammenhang stehende Fragen. Zeitschrift für Mathematik und Physik 1876; 21: 192-218.
5. Helmert FR,. Die Genauigkeit der Formel von Peters zur Berechnung des wahrscheinlichen Beobachtungsfehlers directer Beobachtungen gleicher Genauigkeit Astronomische. Nachtrichten 1876; 88: 113-32.
6. Lüroth J,. Vergleichung von zwei Werten des wahrscheinlichen Fehlers. Astronomische Nachtrichten 1876; 87: 209-20.
7. Edgeworth FY,. The method of least squares. The London, Edinburgh, and Dublin Philosophical Magazine Series 1883; 5 (16): 360-375.
8. Pearson K, Filon LNG,. Mathematical contributions to the theory of evolution. IV On the probable errors of frequency constants and on the influence of random selection on variation and correlation. Philosophical Transactions of the Royal Society of London Series A 1898; 191: 229-311.
9. Student,. Probable error of a correlation coefficient. Biometrika 1908; 7: 302-310.
10. Thompson W,. On the likelihood that an unknown probability exceeds another in view of the evidence of two samples. Biometrika 1933; 25: 285-294.
11. Cornfield J,. Sequential trials, sequential analysis and the likelihood principle. The American Statistician 1966; 20: 19-23.
12. Cornfield J,. A Bayesian test of some classical hypotheses-with applications to sequential clinical trials. Journal of the American Statistical Association 1966; 61: 577-594.
13. Berry DA,. A case for Bayesianism in clinical trials. Statistics in Medicine 1993; 4: 1377-1393.
14. Spiegelhalter DJ, Freedman LS, Parmar MKB,. Bayesian approaches to randomized trials. Journal of the Royal Statistical Society Series A 1994; 157: 357-416.
15. Ashby D,. Bayesian statistics in medicine: a 25 year review. Statistics in Medicine 2006; 25: 3589-3631.
16. Ashby D, Grieve AP,. 25 years of Bayesian methods in the pharmaceutical industry: a personal, statistical bummel. Pharmaceutical statistics 2007; 6: 261-281.
17. International Conference on Harmonisation. E9:Statistical Principles for Clinical Trials, 1996. http://www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500002928.pdf (Accessed July 2014).
18. FDA Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials.-Draft Guidance for Industry and FDA Staff, 2010. http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ ucm071121.pdf (Accessed July 2014).
19. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF,. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. Journal of the American Medical Association 1996; 276: 637-639.
20. Standards of Reporting Trials Group,. A proposal for structured reporting of randomized controlled trials. Journal of the American Medical Association 1994; 272: 1926-1931.
21. Working Group on Recommendations for Reporting of Clinical Trials in the Biomedical Literature,. Call for comments on a proposal to improve reporting of clinical trials in the biomedical literature: a position paper. Annals of Internal Medicine 1994; 121: 894-895.
22. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M,. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Medicine 2007; 4 (1625): 1654.
23. Little J, Higgins JPT, Ioannidis JPA, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson Y, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N,. Strengthening the Reporting of Genetic Association studies (STREGA)-an extension of the STROBE statement. European Journal of Clinical Investigation 2009; 39: 247-266.
24. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of internal medicine 2009; 151: 264-269.
25. Bossuyt PM, Reitsma JB, Bruns DE, Constantine A, Gatsonis CA, Glasziou PP, Irwig LM, Moher D, Rennie D,. de Vet HCW, and Lijmer JG. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Annals of Internal Medicine 2003; 138: W1-12.
26. Husereau D, Drummond M, Petrou S, Carswell S, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E,. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMC Medicine 2013; 11: 80.
27. Tong A, Sainsbury P, Craig J,. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. International Journal for Quality in Health Care 2007; 19: 349-357.
28. Tong A, Flemming K, McInnes E, Oliver S, Craig J,. Enhancing transparency in reporting the synthesis of qualitative research, ENTREQ. BMC Medical Research Methodology 2012; 12: 181.
29. Davidoff F, Batalden P, Stevens D, Ogrinc G, Mooney S,. Publication guidelines for improvement studies in health care: evolution of the SQUIRE project. Annals of Internal Medicine 2008; 149: 670-676.
30. Gagnier JJ, Gunver KG, Alyman DG, Moher D, Sox HR,. The CARE guidelines: consensus-based clinical case reporting guideline Development. Headache: The Journal of Head and Face Pain 2013; 53: 1541-1547.
31. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jeric K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D,. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Annals of Internal Medicine 2013; 31 (158): 200-207.
32. Lang T, Altman D,. 2013. Basic statistical reporting for articles published in clinical medical journals: the SAMPL Guidelines, Smart P, Maisonneuve H, Polderman A, (eds). Science Editors' Handbook, European Association of Science Editors.
33. Sung L, Hayden J, Greenberg ML, Koren G, Feldman BM, Tomlinson GA,. Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study. Journal of Clinical Epidemiology 2005; 58: 261-268.
34. Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR,. Bayesian methods in health technology assessment: a review. Health Technology Assessment 2000; 4: 1-130.
35. The BaSiS Group,. September 13 2001-last update, Bayesian standards in science (BaSiS). http://lib.stat.cmu.edu/ bayesworkshop/2001/BaSis.html. (Accessed July 2014).
36. Lehmann HP, Goodman SN,. Bayesian Communication A Clinically Significant Paradigm for Electronic Publication. Journal of the American Medical Informatics Association 7 2000; 3: 254-266.
37. Hildreth C,. Bayesian statisticians and remote clients. Econometrica: Journal of the Econometric Society 1963; 31: 422-438.
38. Draper D,. Assessment and propagation of model uncertainty (with discussion). Journal of the Royal Statistical Society Series B (Methodological) 1995; 57: 45-97.
39. Grieve AP,. A Bayesian analysis of the twoperiod crossover design for clinical trials. Biometrics 1985; 41: 979-990.
40. Grieve AP,. Extension of a Bayesian approach to the analysis of the twoperiod crossover to include baselines. Statistics in Medicine 1994; 13: 905-929.
41. LeBlond D,. FDA Bayesian statistics guidance for medical device trials-application to process validation. Journal of Vlaidation Technology 2010; 16: 24-33.
42. Hunter WG, Lamboy WF,. A Bayesian analysis of the linear calibration problem. Technometrics 1981; 23: 323-328.
43. Bickel JE, Floehr E, Kim SD,. Comparing NWS PoP forecasts to third-party providers. Monthly Weather Review 2011; 139: 3304-3321.
44. Rubin DR,. Bayesianly justifiable and relevant frequency calculations for the applies statistician. The Annals of Statistics 1984; 12: 1151-1172.
45. Little R,. Calibrated Bayes: a Bayes/frequentist roadmap. The American Statistician 2006; 60: 213-223.
46. Little R,. Calibrated Bayes for, statistics in general, and missing data in particular. Statistical Science 2011; 26: 162-174.
47. Little RJ,. Calibrated Bayes, an alternative inferential paradigm for official statistics, vol. 28, 2012; 309-334.
48. Grieve AP,. Joint equivalence of means and variances of two populations. Journal of Biopharmaceutical Statistics 1998; 8: 377-390.
49. Bauer P, Bauer MM,. Testing equivalence simultaneously for location and dispersion of two normally distributed populations. Biometrical Journal 1994; 6: 643-660.
50. Medical Research Council Streptomycin in Tuberculosis Trials Committee,. Streptomycin treatment for pulmonary tuberculosis. British Medical Journal 1948; ii: 769-82.
51. Wald A,. Sequential Analysis. John Wiley: New York, 1947.
52. Dodge HF, Romig HG,. A method of sampling inspection. The Bell System Technical Journal 1929; 7: 613-631. Geller NL.
53. Bartky W,. Multiple sampling with constant probability. Annals of Mathematical Statistics 1943; 14: 363-377.
54. Armitage P,. Sequential tests in prophylactic and therapeutic trials. Quarterly Journal of Medicine 1954; 23: 255-274.
55. Armitage P,. Sequential methods in clinical trials. American Journal of Public Health 1958; 48: 1395-1402.
56. Bross I,. Sequential medical plans. Biometrics 1952; 8: 188-205.
57. Bross I,. Sequential clinical trials. Journal of Chronic Diseases 1958; 8: 349-365.
58. Armitage P,. Sequential Medical Trials, 2nd Edition. Blackwell Scientific: Oxford, 1975.
59. Armitage P, McPherson CK,. Repeated significance tests on accumulating data. Journal of the Royal Statistical Society Series A 1969; 132: 235-244.
60. Haybittle JL,. Repeated assessment of results in clinical trials of cancer treatment. British Journal of Radiology 1971; 44: 793-797.
61. Pocock SJ,. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977; 64: 191-199.
62. Pocock SJ,. Interim Analyses for randomized clinical trials: the group sequential approach. Biometrics 1982; 38: 153-162.
63. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG,. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. British Journal of Cancer 1976; 34: 585-612.
64. O'Brien PC, Fleming TR,. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-556.
65. Lan KKG, DeMets DL,. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-663.
66. Berry DA,. Interim analysis in clinical trials: classical vs. Bayesian approaches. Statistics in Medicine 1985; 4: 521-526.
67. Berry DA,. Interim analysis in clinical trials: the role of the likelihood principle. The American Statistician 1987; 41: 117-122.
68. Freedman LS, Spiegelhalter DJ,. Comparison of Bayesian with group sequential methods for monitoring. Controlled Clinical Trials 1989; 10: 357-367.
69. Lewis RJ, Berry DA,. A classical evaluation of Bayesian decision-theoretic designs. Journal of the American Statistical Assoication 1994; 89: 1528-1534.
70. Freedman LS, Spiegelhalter DJ, Parmar MKB,. The what, why and how of Bayesian clinical trials monitoring. Statistics in Medicine 1994; 13: 1371-1383.
71. Fayers PM, Ashby D, Parmar MKB,. Bayesian data monitoring in clinical trials. Statistics in Medicine 1997; 16: 1413-1430.
72. Cronin KA, Freedman LS, Lieberman R, Weiss HL, Beenken SW, Kelloff GJ,. Bayesian monitoring of Phase II trials in cancer chemoprevention. Journal of Clinical Pharmacology 1999; 8: 705-711.
73. Parmar MKB, Griffiths GO, Spiegelhalter DJ, Souhami RL, Altman DG, van der Scheuren E,. Monitoring of large randomised clinical trials: a new approach with Bayesian methods. The Lancet 2001; 358: 375-381.
74. Ashby D, Tan S-B,. Where's the utility in Bayesian data-monitoring of clinical trials. Clinical Trials 2005; 2: 197-208.
75. Goodman SN,. Stopping at nothing? Some dilemmas of data monitoring in clinical trials. Annals of Internal Medicine 2007; 46: 882-888.
76. Emerson SS, Kittelson JM, Gillen DL,. Bayesian evaluation of group sequential trial designs. Statistics in Medicine 2007; 26: 1431-1449.
77. Gsponer T, Gerber F, Bornkamp B, Ohlssen D, Vandemeulebroecke M, Schmidli H,. A practical guide to Bayesian group sequential designs. Pharmaceutical statistics 2014; 13: 71-80.
78. Grossmann J, Parmar MK, Spiegelhalter DJ, Freedman LS,. A unified method for monitoring and analysing controlled trials. Statistics in Medicine 1994; 13: 1815-1826.
79. Pennello G, Thompson L,. Experience with reviewing Bayesian medical device trials. Journal of Biopharmaceutical Statistics 2007; 18: 81-115.
80. Reboussin DM, DeMets DL, Kim KM, Lan KKG,. Computations for Group Sequential Boundaries Using the Lan-DeMets Spending Function Method. Controlled Clinical Trials 2000; 21: 190-207.
81. O'Hagan A, Stevens JW,. Bayesian assessment of sample size for clinical trials of cost-effectiveness. Medical Decision Making 2001; 21: 219-230.
82. Senn S,. Consensus and controversy in pharmaceutical statistics (with discussion). Journal of the Royal Statistical Society: Series D (The Statistician) 2000; 49: 135-176.
83. Neuenschwander B, Capkun-Niggli G, Branson M, Spiegelhalter DJ,. Summarizing historical information on controls in clinical trials. Clinical Trials 2010; 7: 5-18.
84. Di Scala L, Kerman J, Neuenschwander B,. Collection, synthesis, and interpretation of evidence: a proof-of-concept study in COPD. Statistics in Medicine 2013; 32: 1621-1634.
85. Viele K, Berry S, Neuenschwander B, Amzal B, Chen F, Enas N, Hobbs B, Ibrahim JG, Kinnersley N, Lindborg S, Micalle S, Roychoudhury S, Thompson L,. Use of historical control data for assessing treatment effects in clinical trials. Pharmaceutical Statistics 2014; 13: 41-54.
86. Alber SA, Lee JJ,. Calibrating the Prior Distribution for a Normal Model with Conjugate Prior, 2015. To appear.
87. Grieve AP, Krams M,. ASTIN: a Bayesian adaptive dose-response trial in acute stroke. Clinical Trials 2005; 2: 340-351.
88. Thall PF, Wathen JK,. Practical Bayesian adaptive randomisation in clinical trials. European Journal of Cance 2007; 43: 859-866.
89. Altham PME,. Exact Bayesian analysis Of a 2x2 contingency table, and Fisher's «Exact» significance test. Journal Of The Royal Statistical Society Series B 1969; 31: 261-269.
90. Liebermeister C,. Über Wahrscheinlichkeitsrechnung in Anwendung auf therapeutische Statistik. Sammlung klinischer Vorträge 1877; 110: 935-962.
91. Seneta E, Carl Liebermeister's Hypergeometric Tails,. Historia Mathematica 1994; 21: 453-462.
92. Ineichen R,. Der «Vierfeldertest» von Carl Liebermeister (Bemerkungen zur Entwicklung der medizinischen Statistik im 19. Jahrhundert). Historia Mathematica 1994; 21: 28-38.
93. Seneta E, Seif FJ, Liebermeister H, Dietz K,. Carl Liebermeister (1833-1901): a pioneer of the investigation and treatment of fever and the developer of a statistical test. Journal of Medical Biography 2004; 12: 215-221.
94. Thompson W,. On the theory of apportionment. American Journal of Mathematics 1935; 57: 450-456.
95. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DCX, Schuetze SM, Reinke D, Thall PF, Benjamin RS,. Baker LH, and Hensley ML Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. Journal of Clinical Oncology 2007; 25: 2755-2763.
96. Giles FJ, Kantarjian HM, Cortes JE, Garcia-Manero G, Verstovsek S, Faderl S, Thomas DA, Ferrajoli A, O'Brien S, Wathen JK, Xiao LC, Berry DA, Estey EH,. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. Journal of Clinical Oncology 2003; 21: 1722-1727.
97. Korn EL, Freidlin B,. Outcome-adaptive randomization: Is it useful? Journal of Clinical Oncology 2011; 29: 771-776.
98. Berry DA,. Adaptive clinical trials: the promise and the caution. Journal of Clinical Oncology 2011; 29: 606-609.
99. Thall PF, Fox PS, Wathen JK, Some Caveats for Outcome Adaptive Randomization in Clinical Trials,. 2015. In Modern Adaptive Randomized Clinical Trials: Statistical, Operational, and Regulatory Aspects, Sverdlov O, (ed.). CRC Press: Boca Raton; 287-305. in press.
100. Giovagnoli A, Zagoraiou M,. Simulation of clinical trials: a review with emphasis on the design issues. Statistica 2012; 72: 63-80.
101. Holford NHG, Hale M, Ko HC, Steimer J-L, Sheiner LB, Peck CC,. Simulation in drug development, October 2014. Good Practices, 1999. Available at http://bts.ucsf.edu/cdds/research/sddgpreport.php Accessed.
102. Daniel C,. Use of half-normal plots in interpreting factorial two-level experiments. Technometrics 1959; 1: 311-341.
103. Box GEP, Meyer RD,. An analysis for unreplicated fractional factorials.Technometrics 1986; 28: 11-18.
104. Lenth RV,. Quick and easy analysis of unreplicated factorials. Technometrics 1989; 31: 469-473.
105. Posch M, Maurer W, Bretz F,. Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim. Pharmaceutical statistics 2011; 10: 96-104.
106. Hammersley JM, Morton KW,. A new Monte Carlo technique: antithetic variates. Mathematical Proceedings of the Cambridge Philosophical Society 1956; 52: 449-475.
107. Wang S-J, Bretz F,. From adaptive design to modern protocol design for drug development: part I. Editorial and summary of adaptive designs session at the third FDA/DIA statistics forum. Drug Information Journal 2010; 44: 325-331.
108. Mudge JF, Baker LF, Edge CB, Houlahan JE,. Setting an optimal α that minimizes errors in null hypothesis significance tests. PLoS ONE 2012; e32734: 7.
109. Pericchi LR and Pereira CAB. Changing the paradigm of fixed significance levels: Testing Hypothesis by Minimizing Sum of Errors Type I and Type II. Brazilian Journal of Probability and Statistics 2015, to appear.
110. Grieve AP,. How to test hypotheses if you must. Pharmaceutical Statistics 2015; 14: 139-150.